OncoSil Medical: Half Yearly Report Results
Filed with ASX · · 3 pages · English
Sydney, Australia – 22 February 2022: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with pancreatic cancer, is pleased to report its financial results for the half year ended 31 December 2021 (the Half-Year) (the Financial Report) and its Appendix 4D. All financial results are in Australian dollars and are unaudited.
Earlier from OncoSil Medical
- OncoSil approved for Innovation Funding (NUB) in Germany
- PanCO Clinical Study on OncoSil Published in ESMO Open
- 2021 AGM CEO Presentation
- Receipt of $1.077m R&D Tax Incentive Refund
- OncoSil TGA regulatory update
Later from OncoSil Medical
- Fully-Funded Trial Approved In Germany
- First Commerical Pancreas Treatment In Spain
- OncoSil Signs Commercial Agreement With Hospital In Spain
- OncoSil Launches $10m Capital Raising
- Clarification Of Non-Renouncable Entitlement Offer Details
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical